E
Enzo Bonmassar
Researcher at University of Rome Tor Vergata
Publications - 255
Citations - 6086
Enzo Bonmassar is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Cytotoxic T cell & Antigen. The author has an hindex of 39, co-authored 254 publications receiving 5845 citations. Previous affiliations of Enzo Bonmassar include Sapienza University of Rome & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
miR-155 gene: a typical multifunctional microRNA.
TL;DR: The available experimental evidence indicating that miR-155 is over expressed in a variety of malignant tumors allows us to include this miRNA in the list of genes of paramount importance in cancer diagnosis and prognosis.
Journal ArticleDOI
Involvement of the mismatch repair system in temozolomide-induced apoptosis
Stefania D'Atri,Lucio Tentori,Pedro Miguel Lacal,Grazia Graziani,Elena Pagani,Elena Benincasa,Giovanna Zambruno,Enzo Bonmassar,Josef Jiricny +8 more
TL;DR: The existence of a link between a functional mismatch repair system and the trigger of apoptosis in cells exposed to clinically relevant concentrations of temozolomide is demonstrated and the results suggest that p53 induction in response to O6-guanine methylation involves the mismatchrepair system.
Journal ArticleDOI
Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro
TL;DR: The present results support the hypothesis that 5-FU can alter profoundly miR gene expression pattern and could be responsible, at least in part, of the multi-target pleiotropic influence manifested by the drug on malignant cells.
Journal ArticleDOI
DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
Simona Caporali,Sabrina Falcinelli,Giuseppe Starace,Maria Teresa Russo,Enzo Bonmassar,Josef Jiricny,Stefania D'Atri +6 more
TL;DR: It is demonstrated that TMZ treatment activates ATM- and ATR-dependent signaling pathways and that this process is absolutely dependent on functional MMR only at low drug concentrations.
Journal ArticleDOI
Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients
Pierpaolo Correale,Maria Grazia Cusi,Kwong Y. Tsang,Maria Teresa Del Vecchio,Stefania Marsili,Marco La Placa,C. Intrivici,Angelo Aquino,Lucia Micheli,Cristina Nencini,Francesco Ferrari,Giorgio Giorgi,Enzo Bonmassar,Guido Francini +13 more
TL;DR: The results show that the gemcitabine + FOLFOX-4 polychemotherapy regimen has strong immunologic and antitumor activity in colorectal cancer patients and deserves to be investigated in phase III trials.